Drugs·1 SepPlasma Biomarker Effects of Oral Valiltramiprosate/ALZ-801 in Early Alzheimer's Disease from Phase 3 and Phase 2 Trials: Analysis of Core Biomarkers and Correlations with Clinical and Neuroimaging OutcomesTrial in peopleInterventionsPaper
Research Square·25 AugQuantitative Systems Pharmacology Analysis of Amyloid Aggregation and Hippocampal Atrophy Trajectories in Alzheimer’s Disease by APOE4 Genotype and Valiltramiprosate/ALZ-801 TreatmentPreprint: computational studyInterventionsPaper
AAIC 2025 Abstract·23 DecValiltramiprosate/ALZ‐801 Prevents Hippocampal Atrophy and Clinical Decline in a Stage 2 AD Subpopulation in APOLLOE4 Phase 3 StudyTrial in peopleInterventionsPaper
AAIC 2025 Abstract·23 DecQuantitative System Pharmacology Analysis of Oral Valiltramiprosate/ALZ‐801 Predicts Slowing of Alzheimer’s Disease Progression by Anti‐Amyloid Oligomer and APOE4 Structural Corrector Modes of ActionComputational studyInterventionsPaper
AAIC 2025 Abstract·23 DecQuantitative Systems Pharmacology Analysis of Hippocampal Volume Trajectory by APOE Genotype and Neuroprotective Effects of Valiltramiprosate/ALZ‐801 in Early ADComputational studyInterventionsPaper